Correlation Between Israel China and Infimer

Can any of the company-specific risk be diversified away by investing in both Israel China and Infimer at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Israel China and Infimer into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Israel China Biotechnology and Infimer, you can compare the effects of market volatilities on Israel China and Infimer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Israel China with a short position of Infimer. Check out your portfolio center. Please also check ongoing floating volatility patterns of Israel China and Infimer.

Diversification Opportunities for Israel China and Infimer

-0.5

Correlation Coefficient

Israel China  Infimer

Very good diversification

The 3 months correlation between Israel and Infimer is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Israel China Biotechnology and Infimer in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Infimer and Israel China is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Israel China Biotechnology are associated (or correlated) with Infimer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Infimer has no effect on the direction of Israel China i.e., Israel China and Infimer go up and down completely randomly.

Pair Corralation between Israel China and Infimer

Assuming the 90 days trading horizon Israel China Biotechnology is expected to under-perform the Infimer. But the stock apears to be less risky and, when comparing its historical volatility, Israel China Biotechnology is 87.33 times less risky than Infimer. The stock trades about -0.06 of its potential returns per unit of risk. The Infimer is currently generating about 0.36 of returns per unit of risk over similar time horizon. If you would invest  4,700  in Infimer on September 18, 2024 and sell it today you would earn a total of  995,300  from holding Infimer or generate 21176.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	97.83%
Values	Daily Returns

Israel China Biotechnology  vs.  Infimer

Israel China Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Israel China Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Infimer

Risk-Adjusted Performance

28 of 100

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Infimer are ranked lower than 28 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Infimer sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Israel China and Infimer

The main advantage of trading using opposite Israel China and Infimer positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Israel China position performs unexpectedly, Infimer can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Infimer will offset losses from the drop in Infimer's long position.

The idea behind Israel China Biotechnology and Infimer pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.